ARTICLE | Finance
Safety first
Safety data enabled antibiotics play VenatoRx to attract institutional investors
July 29, 2017 1:23 AM UTC
Phase I safety data for VNRX-5133 enabled VenatoRx Pharmaceuticals Inc. to bring its first institutional investors on board for a $42 million series B round.
Versant Ventures led the tranched round on July 25, joined by Abingworth and Foresite Capital. Details of the tranches are undisclosed...
BCIQ Company Profiles
BCIQ Target Profiles